Lilly's cancer therapy Lartruvo fails to meet main goal in late-stage trial

Eli Lilly and Co said on Friday its cancer treatment Lartruvo failed to meet the main goal in a late-stage trial testing the therapy in patients with advanced or metastatic soft tissue sarcoma.